
Ptc Therapeutics (PTCT) | Stock Overview & Key Data
Ptc Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $78.72 on April 6, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
Ptc Therapeutics PTCT | 5.19B Mid-cap | -2.46% | 19.27% | 19.05% | 6.65% | 28.57% | 57.06% | 17.51% | 23.00% |
Vertex VRTX | 103.40B Large-cap | 4.55% | 1.68% | -12.25% | -16.68% | -0.61% | -11.42% | 36.61% | 49.40% |
Regeneron REGN | 63.78B Large-cap | 6.40% | 6.42% | 9.62% | -1.74% | -16.11% | -40.76% | -16.94% | -0.34% |
Madrigal MDGL | 9.87B Mid-cap | 4.43% | 1.78% | 48.23% | 35.44% | 41.18% | 112.57% | 490.44% | 241.88% |
Bio-Techne TECH | 9.80B Mid-cap | 21.41% | 18.02% | 18.46% | 14.75% | -11.93% | -15.82% | -14.93% | -5.01% |
Corcept Therapeutics CORT | 9.29B Mid-cap | 5.10% | 23.56% | 21.97% | 11.06% | 76.41% | 94.03% | 232.89% | 380.38% |
Ownership & Short Interest
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PTCT's 52-week high and low?
- In the last 52 weeks, Ptc Therapeutics reached a high of $58.38 (on March 17, 2025) and a low of $28.72 (on June 28, 2024).
- What is the market cap and P/E ratio for PTCT?
- Curious about Ptc Therapeutics's size and valuation? Its market capitalization stands at 5.19B. When it comes to valuation, the P/E ratio (trailing twelve months) is 9.27, and the forward P/E (looking ahead) is -17.76.
- Does PTCT pay dividends? If so, what's the yield?
- As for dividends, Ptc Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ptc Therapeutics's main competitors or similar companies to consider before investing?
When looking at Ptc Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX103.40B Healthcare Biotechnology -11.42% 36.61% Regeneron
REGN63.78B Healthcare Biotechnology -40.76% -16.94% Madrigal
MDGL9.87B Healthcare Biotechnology 112.57% 490.44% Bio-Techne
TECH9.80B Healthcare Biotechnology -15.82% -14.93% Corcept Therapeutics
CORT9.29B Healthcare Biotechnology 94.03% 232.89% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ptc Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Ptc Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 33.08%, the Debt to Equity ratio from the most recent quarter is -12.03, and its Gross Profit Margin stands at 93.62%.
- What is the recent revenue and earnings growth for PTCT?
- Looking at Ptc Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by -4.20%, and quarterly earnings saw a YoY growth of -4.19%.
- How much of PTCT stock is held by insiders and institutions?
- Wondering who owns Ptc Therapeutics stock? Company insiders (like executives and directors) hold about 2.46% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 101.89%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.